Related Drugs
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Fuzhou FU Yao Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Fuan Pharmaceutical Group Ningbo Team Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Hainan Tongyong Kangli Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Henan FUREN Huaiqingtang Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Topfond Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Reyoung Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Wuhan Aimin Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Southwest Pharmaceutical Co., Ltd.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for
Manufacturer:
Jiangsu Langou Pharmaceutical Co., Ltd.